Trial · NCT07907419
Effect of a Health Belief Model Based Digital Nudge Intervention on Breast Cancer Screening
NCT07907419, Not applicable, Not yet recruiting, Ataturk University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of a Health Belief Model Based Digital Nudge Intervention on Breast Cancer Screening. Trials, record NCT07907419. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07907419
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of a Health Belief Model Based Digital Nudge Intervention on Breast Cancer Screening
- NCT number
- NCT07907419
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 64 participants, estimated
- Lead sponsor
- Ataturk University
- Conditions
- Breast Cancer Screening, Breast Cancer Awareness, Health Belief Model
- Interventions
- Multicomponent Digital Nudge Intervention Based on the Health Belief Model
- First posted
- 2026-10-30
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mammography Screening Behavior | 3 months after completion of the 6-week intervention. | It will be assessed whether women have undergone mammography screening. Screening behavior will be classified as "yes" or "no" based on participants' responses to the question: "Have you had a mammogram in the last 3 months?" With participants' consent and the necessary permissions, self-reported mammography uptake will be verified using records from the Cancer Early Diagnosis, Screening and Education Center. In the primary analysis, the proportion of women who underwent mammography during the follow-up period will be compared between the intervention and control groups. |
| Other | Breast Cancer Awareness Scale | At baseline and immediately after completion of the 6-week intervention. | The Breast Cancer Awareness Scale was developed by Rakkapao et al. (2016); the Turkish validity and reliability study was conducted by Altuntuğ et al. (2021). The scale consists of 29 items and five subscales. The subscales of the scale are: Knowledge of Risk Factors, Knowledge of Signs and Symptoms, Attitudes Toward Breast Cancer Prevention, Barriers to Breast Screening, and Health Behaviors Related to Breast Cancer Awareness. The total score on the scale ranges from 29 to 145. A higher total score on the scale indicates a higher level of awareness among individuals regarding breast cancer risk factors, signs and symptoms, prevention methods, and screening behaviors. The scale's overall Cronbach's alpha coefficient is 0.71, while the Cronbach's alpha coefficients for the subscales range from 0.61 to 0.88. |
| Other | Mammography Health Belief Model Scale | At baseline and immediately after completion of the 6-week intervention. | The Turkish validity and reliability study of the scale developed by Champion (1984) was conducted by Gözüm and Aydın (2004). The scale consists of 52 items and eight subscales. Subscales: sensitivity, anxiety/seriousness, health motivation, perceived benefits of self-breast examination, perceived barriers to self-breast examination, perceived self-efficacy/confidence in self-breast examination, perceived benefits of mammography, and perceived barriers to mammography. In this study, the scale's subscales of sensitivity, seriousness, health motivation, perceived benefits of mammography, and perceived barriers to mammography will be used. These subscales consist of 30 items. The scale's possible score range is between 30 and 150. The scale's Cronbach's alpha coefficients range from 0.69 to 0.83. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07907419
GET https://conductscience.org/api/trials/v1/NCT07907419/registered